Drug Type CRISPR/Cas9 |
Synonyms- |
Target |
Action modulators |
Mechanism ST3GAL5 modulators(ST3 beta-galactoside alpha-2,3-sialyltransferase 5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amish Infantile Epilepsy Syndrome | Preclinical | United States | 01 Sep 2024 |